Literature DB >> 11756407

Identification of fructose 6-phosphate- and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase.

Maria Veiga-da-Cunha1, Emile Van Schaftingen.   

Abstract

Glucokinase is inhibited in the liver by a regulatory protein (GKRP) whose effects are increased by Fru-6-P and suppressed by Fru-1-P. To identify the binding site of these phosphate esters, we took advantage of the homology of GKRP to the isomerase domain of GlmS (glucosamine-6-phosphate synthase) and created 12 different mutants of rat GKRP. Mutations of three residues predicted to bind to Fru-6-P resulted in proteins that were approximately 5-fold (S110A) and 50-fold (S179A and K514A) less potent as inhibitors of glucokinase and had an at least 100-fold reduced affinity for the effectors. Mutation of another residue of the putative binding site (T109A) resulted in a 10-fold decrease in the inhibitory power and an inversion of the effect of sorbitol-6-P, a Fru-6-P analog. The replacement of Gly(107), a residue close to the binding site, by cysteine (as in GlmS and Xenopus GKRP) resulted in a protein that had 20 times more affinity for Fru-6-P and 30 times less affinity for Fru-1-P. These results are consistent with GKRP having one single binding site for phosphate esters. They also show that a missense mutation of GKRP can lead to a gain of function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11756407     DOI: 10.1074/jbc.M105984200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  The biochemical basis of hereditary fructose intolerance.

Authors:  Nadia Bouteldja; David J Timson
Journal:  J Inherit Metab Dis       Date:  2010-02-17       Impact factor: 4.982

2.  Turning enzymes ON with small molecules.

Authors:  Julie A Zorn; James A Wells
Journal:  Nat Chem Biol       Date:  2010-03       Impact factor: 15.040

3.  In vivo and in vitro evidence that chronic activation of the hexosamine biosynthetic pathway interferes with leptin-dependent STAT3 phosphorylation.

Authors:  Arthur D Zimmerman; Ruth B S Harris
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-01-07       Impact factor: 3.619

4.  Structural basis for regulation of human glucokinase by glucokinase regulatory protein.

Authors:  Tobias Beck; Brian G Miller
Journal:  Biochemistry       Date:  2013-08-26       Impact factor: 3.162

Review 5.  Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism.

Authors:  Anne Raimondo; Matthew G Rees; Anna L Gloyn
Journal:  Curr Opin Lipidol       Date:  2015-04       Impact factor: 4.776

6.  Dynamics and control of the central carbon metabolism in hepatoma cells.

Authors:  Klaus Maier; Ute Hofmann; Matthias Reuss; Klaus Mauch
Journal:  BMC Syst Biol       Date:  2010-04-28

7.  Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics.

Authors:  Franz M Matschinsky; Daniel Porte
Journal:  F1000 Med Rep       Date:  2010-06-16

Review 8.  Assessing the potential of glucokinase activators in diabetes therapy.

Authors:  Franz M Matschinsky
Journal:  Nat Rev Drug Discov       Date:  2009-04-17       Impact factor: 84.694

9.  Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase.

Authors:  Jung Min Choi; Moon-Hyeong Seo; Hyun-Ho Kyeong; Eunkyung Kim; Hak-Sung Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-03       Impact factor: 11.205

10.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.

Authors:  Nicola L Beer; Nicholas D Tribble; Laura J McCulloch; Charlotta Roos; Paul R V Johnson; Marju Orho-Melander; Anna L Gloyn
Journal:  Hum Mol Genet       Date:  2009-07-30       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.